About This Publication:

  • Print This Page
  • Text a Friend
  • Subscribe to an RSS Feed

Sample Content 

My Liebert Connect

Sign up to stay informed--receive email notifications for this journal

Biopreservation and Biobanking

Editor-in-Chief: Jim Vaught, PhD

ISSN: 1947-5535 • Published Bimonthly • Online ISSN: 1947-5543

Current Volume: 12

Latest Impact Factor* is 1.578

*2013 Journal Citation Reports® published by Thomson Reuters, 2014

For Authors

  • Manuscript Submissions
  • NIH/HHMI Wellcome Trust Policies
  • Self-Archiving Policy
  • Open Access Policy
  • Manuscript Submissions

    Biopreservation and Biobanking is the first journal to provide a unifying forum for researchers from academia, government, and industry in which rapid, authoritative, peer-reviewed communication of recent advances is provided in the rapidly emerging field of biospecimen procurement, processing, preservation, and banking. The Journal publishes a diversity of articles focusing on current issues and problems related to the processing of macromolecules, cells, and tissues.

    A wide range of topics related to the fundamentals of the basic biopreservation sciences, biosafety, and the ethical, legal and societal issues surrounding biobanking and biorepository operation will be addressed in the Journal.

    Formats. Original research manuscripts should not exceed 3,000 words and must be presented in the standard format described below. Short reports and case studies should not exceed 1,000 words with no more than ten references and one table or figure. Editorials and commentaries may be on any issue relevant to the field, but must be brief and appropriately documented by data. Review papers, of up to 5,000 words in length, are summaries of developments in the field. All submissions will be subjected to peer-review.


    Manuscripts must be submitted online using the following URL: http://mc.manuscriptcentral.com/BiopreservBiobank Authorship. All authors, including the co-authors, should be responsible for a significant part of the manuscript. All authors and co-authors should havetaken part in writing the manuscript, reviewing it, and revising its intellectual and technical and all must sign the cover letter accompanying the manuscript. Any author whose name appears on a paper assumes responsibility and accountability for the results.


    Prepare entire manuscript in Microsoft Word. Include figure legends, double-spaced (6 mm minimum), with ample margins (minimum 1 in.) on all sides. Number pages consecutively.

    Title page. The title page should include the authors' names and affiliations, a running title of about 45 characters (including spaces), and the full contact information for the corresponding author (i.e., mailing and/or street address, telephone and fax numbers, and e-mail address.)

    Abstract. Provide a structured abstract of no more than 300 words.

    Text. Organize the text as follows: Introduction, Materials and Methods, Results, Discussion, Acknowledgments, and References. At the first usage of a term, spell out the term and give the abbreviation or acronym in parentheses. Thereafter, use the abbreviation/acronym alone. Use generic names for drugs where possible. If you wish to use a proprietary drug name, the first time it appears use the generic name followed by the proprietary name and manufacturer in parenthesis. If proprietary names must be used, include trademark information. Scientific names that have abbreviations must be spelled out on first occurrence with abbreviation in parenthesis and abbreviated thereafter.

    Acknowledgments. The author should acknowledge only those people and institutions that have made significant contributions to the study. Details of sources of funding must be given and any potential conflicts of interest declared, e.g., financial, personal, political or academic.

    Patients and Study Participants
    All manuscripts must comply with the privacy and confidentiality requirements outlined on the Uniform Requirements for Manuscripts Submitted to Biomedical Journals website. For more information, visit http://www.icmje.org/ethical_5privacy.html  When articles include reports of studies on human subjects, state in the Methods section that an appropriate institutional review board or ethics committee approved the study. Authors who do not have formal ethics review committees should follow the principles of the Declaration of Helsinki. In the Methods section, state that informed consent was obtained from subjects (specify written or verbal).

    The principal author must state that if animals were used experimentally, permission was obtained from the appropriate committee(s), and that the animals were treated humanely and the standards conformed to those of current ethical animal research practices.

    In addition, text and photographs should not reveal any identifying information unless it is essential for scientific purposes (in which case, consent should be obtained). Masking the subjects’ eyes in photographs is often insufficient to protect their identity.


    When reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. When reporting experiments on animals, authors should indicate whether the institutional and national guide for the care and use of laboratory animals was followed.

    *This portion of the Instructions for Authors has been quoted directly from the Uniform Requirements for Manuscripts Submitted to Biomedical Journals website. For more information, visit www.icmje.org/ethical_6protection.html

    Please include within the Materials and Methods your institute's compliance statements for animal experimentation and handling of human tissue. Examples:

    Use of Animals. Animal experimentation complied with local and national requirements, including the UK Coordinating Committee on Cancer Research guidelines for the welfare of animals in experimental neoplasia.37

    37. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Ramond R, Stables J, Stephens T: United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia [second edition]. Br J Cancer 1998;77:1–10.

    Handling of human tissue. Handling of human DRG tissue was carried out according to legal provisions and rules of the medical faculty of the Innsbruck Medical University.


    All authors are expected to disclose any institutional or commercial affiliations that might pose a conflict of interest regarding the publication of a manuscript. Institutional affiliations, as indicated on the title page, should include all corporate affiliations and any funding sources that support the work. Other types of affiliation, including consultantships, honoraria, stock ownership, equity interests, arrangements regarding patents, or other vested interests should be disclosed in the Acknowledgments section.

    Reference. The references should be cited in the text using the numerical order of citation method. The reference list at the end of the paper should be double-spaced and organized numerically by order of citation. List only the first three authors followed by "et al." For accepted papers not yet published, cite the journal and add "in press." If references to personal communications or unpublished data are used, cite them parenthetically in the text, not in the references. Sources for personal communications must provide written approval at the time of submission. References should be presented in Vancouver style as shown below:

    Journal example

    Ellis, P., Muller-Schweinitzer Maintenance of functional activity of human pulmonary arteries after cryopreservation Br. J. Pharmacol. 1991; 103: 1377-1380.

    Book example:

    Toner, M. Nucleation of ice crystals in biological cells. In: Steponkus PL, ed Advances in Low Temperature Biology. London JAI Press; 199 1-52

    Reprint address. After the references, provide the name, address, and e-mail of the person to whom the reprint requests should be directed.

    Tables. Type each table, with its title, on a separate sheet of paper. Use Arabic numerals to number tables. Details of experimental conditions should be included in the table footnotes. Table legends and footnotes should be double-spaced.  Tables should be created in Microsoft Word.


    Please follow the guidelines below when preparing figure files:

    • Do not include any illustrations as part of your text file.
    • Do not prepare any figures in Word as they are not workable.
    • Line illustrations must be submitted at 600 DPI.
    • Halftones and color photos should be submitted at a minimum of 300 DPI.
    • Power Point files cannot be uploaded.
    • Save art as either TIFF or EPS files.  Do NOT submit JPEG files.
    • Color art must be saved as CYMK not RGB. 


    Please do NOT upload a single PDF file containing all of the text, figure, and table files of your paper.  Once all of your files are uploaded on to Manuscript Central, the system will automatically create a PDF proof for you. Prepare a separate list of figure legends, double-spaced, at the end of the manuscript. Magnifications should be included when appropriate. You will be given directions on how to correct any files which do not pass.


    Converting Word or Excel files: Perhaps the best and easiest way to convert Word or Excel files into a format which is suitable for print is to scan them using the below guidelines:

    All files should be scanned at 100% size.
    300 dpi
    Final color mode: cmyk
    Save file as: .tif or .eps

    If you need directions on how to convert a Power Point slide
    to acceptable format go to http://www.liebertpub.com/MEDIA/pdf/ppconvert.pdf 



    Figures, tables, and text taken from other sources must be accompanied by a written statement from both author and publisher granting permission for reproduction. Include written permission from authors to cite unpublished data or papers still in press.


    Reprints may be ordered by following the special instructions that will accompany page proofs, and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher. Reprints ordered after an issue is printed will be charged at a substantially higher rate.


    The Journal is published by Mary Ann Liebert, Inc., 140 Huguenot Street, New Rochelle, NY 10801-5215.  Telephone: (914) 740-2100; fax: (914) 740-2101; E-mail: info@liebertpub.com; web site: www.liebertpub.com

  • NIH/HHMI Wellcome Trust Policies

    NIH Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final accepted paper (after copy-editing and proofreading) to PubMed Central (PMC) on behalf of the authors. Authors need not take any action. The manuscript's public access posting on PMC will occur 12 months after final publication. This service is provided free of charge. Please note that authors may not deposit manuscripts directly to PMC or other sites without permission from Mary Ann Liebert, Inc.

  • Self-Archiving Policy

    Mary Ann Liebert, Inc. is a "blue" publisher (as defined by Sherpa), as we allow self-archiving of post-print (ie final draft post-refereeing) or publisher's version/PDF.

    In assigning Mary Ann Liebert, Inc. copyright, the author retains the right to deposit such a 'post-print' on their own website, or on their institution's intranet, or within the Institutional Repository of their institution or company of employment, on the following condition, and with the following acknowledgement:

    This is a copy of an article published in the [JOURNAL TITLE] © [year of publication] [copyright Mary Ann Liebert, Inc.]; [JOURNAL TITLE] is available online at: http://online.liebertpub.com.

    Authors may also deposit this version on his/her funder's or funder's designated repository at the funder's request or as a result of a legal obligation, provided it is not made publicly available until 12 months after official publication.

  • Open Access Policy

    Choose Liebert Open Access Option!

    Ensure maximum visibility, discoverability, and impact for your article with our Liebert Open Access (OA) Option.

    Your investment guarantees:

    • Immediate, unrestricted global access in 170 countries
    • Maximum visibility for increased readers, citations, and downloads
    • Targeted email announcement highlighting your article to thousands of thought-leaders in your field
    • Rapid, rigorous peer-review and editorial attention
    • Fast Track online-ahead-of-print publication
    • Immediate upload to PubMed Central and other internationally recognized repositories*
    • Recognition on online Table of Contents with exclusive OA icon
    • Compliance with OA funding mandates with no embargo period
    • Savings on future OA article publication
    • Complimentary membership in AuthorCite®, the author services platform exclusively licensed by Mary Ann Liebert, Inc. that delivers the tools you need to maximize your professional impact.

    These valuable benefits are included with a one-time article processing charge (APC). APC charge varies based on journal, membership, and subsequent submissions.

    Contact openaccess@liebertpub.com for questions on article Open Access options. 

     *Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.


    Is your Institution a member of the Liebert Author Advocacy Program?

    The Liebert Author Advocacy Program (LAAP) provides valuable membership benefits for OA publication to institutional and funding organizations, and supports global funding mandates.  Authors who are affiliated with LAAP member institutions receive all the valuable benefits of Liebert OA article publication, and more.

    For details, and to recommend institutional membership visit: www.authoradvocacy.com or contact laap@liebertpub.com 




The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.

Recommended Publications

You may be interested in the following publications:

    Tissue Engineering, Parts A, B, & C

    Tissue Engineering, Parts A, B, & C

    The preeminent, biomedical journal bringing together the principles of engineering and life sciences to advance the field with cutting-edge research and applications on all aspects of tissue growth and regeneration.

    DNA and Cell Biology

    DNA and Cell Biology

    Combining mechanistic and clinical studies from multiple systems in a single resource, the Journal delivers authoritative, peer-reviewed reporting on the latest research in the field of molecular biology.

    Cellular Reprogramming

    Cellular Reprogramming

    Cutting-edge techniques and the latest high-quality research on the etiology, development, and potential treatment of various diseases through reprogramming cellular mechanisms.

    ASSAY and Drug Development Technologies

    ASSAY and Drug Development Technologies

    This authoritative, rapidly peer-reviewed journal features original articles, application-oriented technology reviews, and reports in methodology and technology application.

    Stem Cells and Development

    Stem Cells and Development

    Globally recognized as the trusted source for critical, even controversial coverage of emerging hypotheses and novel findings on stem cells of all tissue types and their potential therapeutic applications.

    Monoclonal Antibodies
    in Immunodiagnosis
    and Immunotherapy

    Monoclonal Antibodies
    in Immunodiagnosis
    and Immunotherapy

    The essential journal for scientists and clinicians in the fields of molecular immunology and immunopathology, and for all those applying molecular immunological methods for experimental and therapeutic purposes.

    Journal of Interferon
    & Cytokine Research

    Journal of Interferon
    & Cytokine Research

    Presents the latest findings and reviews of research covering IFNs and cytokines, their relevance to chronic and acute disease, studies involving cytokine biology, mechanisms of IFN action, and their role in virus infection.

Browse All Publications »